The OncoAlert 🚨Weekly Round Up July 25-31, 2025

This week on The OncoAlert Weekly Round Up, we spotlight precision oncology in action with top-tier studies making headlines:

🧬 Biomarkers in Breast Cancer Immunotherapy
We break down a critical review by Li et al. and Sherene Loi in The Breast on the evolving biomarker landscape for immune checkpoint inhibitors (ICIs) in breast cancer. PD-L1 isn’t enough—so what’s next? TILs, HRD, TMB, and even signals in luminal tumors might hold the key.

🧪 ER+/HER2+ Subtype Shifts with Preop Endocrine Therapy
A translational analysis from the POETIC trial shows how 2 weeks of aromatase inhibitors can flip high-risk luminal B tumors into luminal A—and change everything about treatment decisions.

🧠 Metabolic Warfare in Brain Metastases
From Nature Reviews Cancer, we explore how cancer cells rewire their metabolism to colonize the brain—and why targeting those pathways could change the game.

🚭 Platinum-Ineligible NSCLC: Real-World Wins for Atezolizumab
Post hoc analysis from IPSOS reinforces immunotherapy’s role for frail lung cancer patients previously excluded from platinum therapy.

🔬 Targeting BRAF in NSCLC: Real-World Outcomes from Turkey
Data from the Turkish Oncology Group reveal the strengths—and survival gaps—of D+T versus chemo, especially in the presence of co-mutations.

💥 Pancreatic Cancer Regimens Face Off in GENERATE Trial
A surprise outcome from JCOG1611 as nab-paclitaxel + gemcitabine outpaces mFOLFIRINOX and S-IROX—raising new questions for front-line care.

🧻 Total Neoadjuvant Therapy in Rectal Cancer: Global Perspective
An international analysis confirms that multiple TNT regimens are working in practice—offering real hope in high-risk stage II/III disease.

⚡ Sequencing Matters in mCRPC
New data suggest enzalutamide before 177Lu-PSMA-617 yields better outcomes than abiraterone—highlighting the power of strategic sequencing.

💸 The Hidden Economic Toll on Cancer Caregivers
A sobering study from Australia puts numbers behind the emotional and financial costs borne by informal cancer caregivers—and calls for policy reform.

🚨 Don’t miss this high-impact episode packed with clinical insights, translational breakthroughs, and real-world data that matter for your daily practice.

📲 Stream now on your favorite podcast app